grow
need
broadspectrum
drug
fight
exist
emerg
infecti
diseas
eid
prepar
potenti
bioterror
attack
toxin
new
eid
crisi
reveal
level
unprepared
due
difficulti
predict
pathogen
emerg
imposs
develop
new
drug
within
month
strategi
broadspectrum
drug
discoveri
search
molecul
target
host
compon
indispens
entri
andor
multipl
mani
differ
toxin
pathogen
drug
may
efficaci
unknown
pathogen
emerg
futur
moreov
molecul
activ
host
cell
compon
avoid
risk
drugresist
plant
bacteri
protein
toxin
act
insid
cell
well
intracellular
infecti
pathogen
virus
intracellular
bacteria
parasit
evolv
sophist
strategi
invad
host
cell
share
common
bind
cellsurfac
receptor
trigger
intern
follow
endocyt
intracellular
traffick
pathway
toxin
virus
sometim
bacteria
enter
cell
cytosol
specif
traffick
bacteria
intracellular
parasit
may
subvert
cell
compart
traffick
compon
build
comfort
vacuol
nutrient
conduc
multipl
thu
small
molecul
target
intracellular
traffick
pathway
eg
host
compon
eg
exploit
infecti
agent
exhibit
broad
antiinfecti
action
report
discoveri
abma
novel
broadspectrum
inhibitor
intracellular
toxin
pathogen
abma
identifi
use
cellbas
high
throughput
screen
ht
cell
intox
plant
toxin
abma
protect
mice
nasal
instil
ricin
besid
abma
protect
cell
intox
least
four
bacteri
toxin
infect
three
virus
two
intracellular
bacteria
one
parasit
addit
molecul
toxic
cell
mice
activ
concentr
show
broadspectrum
antipathogen
action
abma
associ
biogenesi
host
cell
late
endosom
le
without
affect
organel
integr
henc
abma
potenti
inhibit
toxin
infecti
pathogen
reli
le
enter
cytosol
build
intracellular
vacuol
previous
perform
cellbas
ht
identifi
small
chemic
compound
activ
ricinmedi
cell
intox
screen
librari
small
molecul
endow
capac
prevent
inhibit
protein
biosynthesi
induc
ricin
treatment
four
hit
confirm
two
hit
name
report
inhibitor
ricin
shigalik
toxin
stx
block
retrograd
transport
insid
host
chembridgetm
compound
amin
abma
fig
discuss
articl
one
hit
screen
bear
hydrophob
adamantan
substitut
aromat
moieti
inhal
consid
major
risk
factor
ricin
thu
abma
protect
activ
first
test
vitro
challeng
human
pulmonari
alveolar
basal
epitheli
cell
increas
concentr
ricin
fig
five
independ
experi
abma
treatment
induc
decreas
ricin
cytotox
protect
factor
r
rang
abma
retain
almost
biolog
activ
ricininduc
cytotox
six
day
incub
cultur
medium
fig
indic
robust
stabil
expect
abma
observ
inhibitori
effect
cell
protein
synthesi
least
measur
leucin
incorpor
fig
cell
viabil
assay
also
confirm
low
toxic
human
cell
cytotox
concentr
cultur
hela
primari
human
cell
human
umbil
vein
endotheli
cell
huvec
fig
base
vitro
result
investig
whether
abma
could
protect
mice
lethal
ricin
challeng
abma
nontox
anim
one
intraperiton
ip
administr
mgkg
model
ricin
intox
nasal
use
mimic
exposur
aerosol
would
occur
intent
releas
briefli
mice
challeng
ricin
day
fig
close
circl
first
clinic
sign
intox
appear
within
h
mice
display
bristli
greasi
hair
day
weight
loss
observ
later
time
point
sign
notic
prostrat
shake
respiratori
distress
anim
need
euthan
start
day
post
exposur
statist
signific
protect
accord
surviv
curv
observ
singl
ip
dose
mgkg
abma
h
prior
toxin
challeng
p
versu
control
fig
open
circl
forti
eight
n
independ
experi
abmatr
mice
surviv
control
group
surviv
n
independ
experi
base
result
addit
experi
perform
escal
dose
abma
administr
singl
ip
dose
mgkg
mgkg
abma
prior
ricin
intox
gave
improv
statist
signific
level
protect
compar
control
group
p
n
group
mgkg
dose
fulli
protect
anim
day
fig
mgkg
dose
result
protect
mice
ricin
challeng
singl
anim
succumb
day
lower
protect
seen
higher
dose
may
due
solubl
issu
abma
aqueou
solut
result
uncertain
biodistribut
highest
dose
mechan
action
ricin
toxin
share
common
gener
principl
intracellularact
bacteri
protein
toxin
bind
cellsurfac
receptor
intern
endocyt
compart
traffick
intracellular
transport
pathway
transloc
transport
vesicl
compart
cytosol
catalyt
modif
cellular
target
thu
investig
effect
abma
bacteri
toxin
may
lead
identifi
sensit
toxin
henc
get
insight
abma
mechan
tabl
summar
featur
test
toxin
appropri
model
cell
line
pretreat
solvent
alon
dmso
variou
concentr
abma
respect
incub
increas
concentr
diphtheria
toxin
corynebacterium
diphtheria
dt
lethal
toxin
bacillu
anthraci
lt
toxin
b
clostridium
difficil
tcdb
lethal
toxin
clostridium
sordellii
tcsl
shigalik
toxin
escherichia
coli
botulinum
neurotoxin
bonta
clostridium
botulinum
tabl
fig
inhibitori
effect
dt
protein
biosynthesi
measur
incorpor
leucin
newli
synthes
protein
observ
higher
level
protein
biosynthesi
cell
expos
dt
presenc
abma
absenc
fig
n
abma
dt
toxic
reduc
assay
condit
also
found
abma
protect
cell
line
eg
vero
well
huvec
primari
cell
dt
data
shown
indic
inhibitori
effect
abma
dt
cell
typespecif
anthrax
lt
cleav
mitogenactiv
protein
kinas
figur
show
cleavag
lt
huvec
partial
inhibit
presenc
abma
tcdb
tcsl
inactiv
small
gtpase
glucosyltransferas
activ
disrupt
actin
cytoskeleton
induc
cell
abma
reduc
vero
cell
round
fold
respect
follow
challeng
tcdb
h
tcsl
h
fig
tcdb
tcsl
n
block
cell
protein
biosynthesi
cleav
adenin
ribosom
rna
nadenin
glycohydrolas
activ
abma
bare
protect
effect
intox
hela
cell
weak
protect
fig
botulinum
neurotoxin
bonta
cleav
snare
protein
essenti
fusion
neuromedi
vesicl
presynapt
membran
nerv
termini
induc
paralysi
neuromuscular
figur
show
abma
unabl
prevent
cleavag
bonta
rat
cerebellar
granul
primari
cultur
neuron
model
bonta
activ
taken
togeth
result
show
abma
effect
bonta
cell
intox
nevertheless
display
broadspectrum
antitoxin
activ
potent
plant
bacteri
toxin
act
insid
cell
ricin
dt
lt
tcdb
tcsl
variou
step
toxin
mechan
action
may
consid
target
abma
receptor
bind
intern
intracellular
traffick
transloc
cell
cytosol
catalyt
modif
cell
substrat
toxin
sensit
abma
differ
catalyt
activ
nadenin
glycohydrolas
ricin
adpribosyltransferas
dt
metalloproteas
anthrax
lt
bonta
glucosyltransferas
tcdb
tcsl
thu
unlik
abma
inhibit
toxin
catalyt
activ
toxin
use
differ
cellsurfac
compon
receptor
cell
bind
intern
see
tabl
thu
abma
probabl
inhibit
bind
toxin
receptor
nevertheless
investig
whether
abma
could
inhibit
bind
dt
receptor
bind
domain
name
receptor
prohbegf
precursor
heparin
bind
epiderm
growth
factor
analog
model
toxinreceptor
fluoresc
made
chemic
coupl
fac
analysi
show
abma
affect
bind
receptor
vero
cell
fig
suggest
inhibit
dt
cytotox
induc
abma
due
reduc
bind
dt
receptor
sinc
abma
inhibit
sever
toxin
differ
catalyt
activ
differ
receptor
hypothes
inhibitor
act
directli
toxin
rather
common
host
target
necessari
toxin
reach
host
cell
cytosol
exert
toxic
result
demonstr
abma
pronounc
inhibitori
effect
dt
lt
tcdb
tcsl
wellcharacter
acid
endosomedepend
toxin
requir
lowph
endosom
earli
endosom
ee
le
undergo
conform
chang
lead
interact
transmembran
catalyt
domain
compart
membran
transloc
catalyt
domain
contrast
abma
bare
protect
effect
intox
hela
cell
follow
exclus
retrograd
rout
ee
endoplasm
reticulum
er
via
golgi
apparatu
intern
final
abma
abl
inhibit
bonta
reli
peculiar
synapt
vesicl
recycl
endocytosi
process
enter
thu
hypothes
abma
target
host
endosom
traffick
pathway
ee
lysosom
know
abma
protect
cell
multipl
toxin
reli
acid
endosom
transloc
cytosol
investig
whether
abma
abl
inhibit
cell
infect
virus
phdepend
mechan
capsid
releas
compart
test
ebola
viru
ebov
rabi
viru
rabv
viru
chikungunya
viru
chikv
tabl
bear
surfac
glycoprotein
mediat
fusion
viru
membran
endosom
capsid
releas
cell
cytosol
initi
hela
cell
incub
h
increas
concentr
abma
infect
recombin
ebov
mayinga
strain
carri
enhanc
green
fluoresc
protein
egfp
abma
treatment
inhibit
ebovegfp
infect
fig
babi
hamster
kidney
bsr
cell
incub
h
abma
infect
pasteur
vaccinspv
strain
rabv
abma
inhibit
infect
fig
ribavirin
antivir
drug
inhibit
viral
rna
synthesi
viral
mrna
cap
use
refer
molecul
exhibit
similar
final
vero
cell
incub
h
abma
infect
abma
inhibit
infect
ribavirin
four
fold
less
effici
protect
cell
infect
fig
abma
reduc
cell
infect
three
virus
least
ebov
rabv
contrast
abma
inhibit
infect
cell
chikungunya
viru
chikv
fig
see
discuss
section
summari
observ
abma
inhibit
three
endosom
virus
simkaniacea
chlamydiacea
order
chlamydial
oblig
intracellular
gramneg
pathogen
bacteria
use
hostcel
materi
form
distinct
degradationresist
replicationpermiss
membran
compart
vacuol
inclus
despit
differ
intracellular
lifestyl
share
sever
common
featur
proteom
character
simkania
negevensi
sn
contain
vacuol
sncv
shown
contain
protein
sever
main
host
transport
pathway
includ
endosom
chlamydia
trachomati
ctr
recruit
multipl
rab
protein
endosom
inclus
membran
avoid
travel
phagolysosom
final
besid
golgi
apparatu
multivesicular
bodi
mvb
also
known
le
anoth
essenti
sourc
cholesterol
sphingomyelin
develop
ctr
thu
test
whether
abma
could
inhibit
infect
cell
sn
ctr
figur
show
abma
sharpli
reduc
amount
sn
infect
cell
reveal
immunoblot
sn
heatshock
protein
parallel
inclus
size
smaller
reveal
immunofluoresc
fig
sn
progeni
harvest
abmatr
cell
reduc
amount
sn
fig
number
inclus
upon
infect
fresh
untreat
cell
fig
e
abma
slightli
reduc
cellular
load
gfpexpress
ctr
strain
primari
infect
seen
ctr
immunoblot
fig
howev
abma
treatment
dramat
reduc
chlamydi
progeni
infect
indic
reduc
inclus
number
bacteri
load
fig
b
togeth
result
show
abma
inhibit
capac
sn
ctr
develop
properli
cell
infect
lead
progeni
reduc
infect
monocyt
macrophag
import
target
cell
pathophysiolog
leishmania
parasit
parasit
intern
develop
amastigot
form
within
parasitophor
vacuol
incorpor
endolysosom
pathway
thu
investig
whether
abma
could
inhibit
infect
raw
macrophag
leishmania
infantum
amastigot
amphotericin
b
miltefosin
approv
drug
clinic
manag
leishmaniasi
use
refer
drug
tabl
show
three
drug
inhibit
l
infantum
intramacrophag
amastigot
develop
variou
abma
around
interestingli
two
refer
drug
capabl
inhibit
axen
amastigot
efficaci
similar
found
intramacrophag
amastigot
wherea
abma
direct
effect
axen
parasit
addit
abma
cytox
lower
refer
drug
result
strongli
suggest
abma
block
l
infantum
intracellular
develop
action
host
cell
drug
directli
toxic
parasit
determin
abma
inhibit
intox
infect
cell
varieti
toxin
virus
intracellular
microorgan
toxin
virus
reli
endosom
acidif
enter
cytosol
bacteria
parasit
build
vacuol
incorpor
endosom
membran
protein
acquir
nutrient
prolifer
may
suggest
abma
target
modifi
acid
endosom
homeostasi
observ
confoc
microscopi
live
cell
treat
abma
stain
deep
red
exhibit
intens
label
enlarg
fluoresc
puncta
cell
treat
dmso
fig
middl
left
panel
respect
contrast
bafilomycin
baf
highli
specif
vatpas
inhibitor
prevent
endosom
acidif
decreas
fluoresc
stain
cell
fig
right
panel
obtain
similar
result
abma
baf
hela
raw
cell
data
shown
confirm
abma
affect
acid
endosom
use
acridin
orang
anoth
cellperm
dye
acid
organel
fig
central
lower
panel
similarli
abma
induc
larger
brighter
red
fluoresc
vesicl
cell
contrast
effect
baf
strongli
decreas
red
fluoresc
cytoplasm
vesicl
altogeth
abma
effect
acid
compart
differ
baf
baf
known
inhibit
dt
toxic
inhibit
endosom
acidif
might
expect
combin
effect
molecul
might
annihil
impact
increas
endosom
acidif
abma
versu
decreas
acidif
surprisingli
abma
combin
baf
inhibitori
effect
dt
cytotox
twenti
fold
higher
molecul
alon
fig
strongli
suggest
abma
baf
differ
mechan
action
distinct
target
moreov
indic
antitoxin
antipathogen
effect
abma
link
increas
endosom
acidif
otherwis
would
counter
balanc
baf
character
effect
abma
intracellular
acid
compart
immunostain
protein
marker
ee
lysosom
pathway
perform
cell
immunostain
ee
marker
fig
upper
panel
lysosom
marker
fig
lower
panel
unchang
abmatr
cell
vehicl
alon
le
marker
import
gtpase
late
endocyt
pathway
stain
visibl
enhanc
abmatr
cell
compar
vehicl
alon
fig
central
panel
importantli
observ
morpholog
chang
import
cellular
organel
golgi
apparatu
er
stain
transgolgi
network
tgn
protein
disulfid
isomeras
pdi
respect
fig
well
endocytosisrel
membran
protein
clathrin
epsin
data
shown
altogeth
data
show
abma
target
late
endosom
compart
without
affect
morpholog
organel
ee
golgi
apparatu
er
lysosom
besid
ee
le
consid
import
complex
sort
station
protein
lipid
endocyt
pathway
cholesteryl
ester
lelysosom
hydrolyz
lysosom
acid
lipas
free
cholesterol
egress
endolysosom
system
allow
distribut
cellular
investig
le
modifi
abma
consequ
accompani
alter
cholesterol
transport
may
potenti
interfer
nutrit
intracellular
filipin
iii
fluoresc
probe
high
affin
cholesterol
appli
cell
treat
respect
dmso
abma
intracellular
cholesterol
transport
inhibitor
abma
induc
accumul
cholesterol
insid
hela
cell
observ
fluoresc
microscopi
fig
togeth
data
show
abma
affect
le
induc
cholesterol
accumul
like
within
late
endosom
compart
enhanc
lysotrack
acidif
dye
stain
led
us
investig
abma
affect
number
morpholog
le
use
transmiss
electron
microscopi
examin
ultrastructur
morpholog
organel
dmso
abmatr
cell
observ
abma
induc
accumul
compart
nm
size
contain
variabl
number
smaller
intralumin
vesicl
ilv
lack
multilamellar
morpholog
fig
structur
characterist
multivesicular
bodiesl
mvbsle
organel
appear
electrondens
multilamellar
membran
compart
characterist
lysosom
visual
dmso
abmatr
cell
without
observ
differ
amount
morpholog
fig
altogeth
result
show
abma
induc
accumul
mvbsle
report
small
molecul
abma
origin
cellbas
ht
assay
identifi
ricin
protect
cell
wide
rang
bacteri
toxin
virus
intracellular
microorgan
includ
bacteria
parasit
efficaci
abma
variabl
accord
pathogen
toxin
investig
valu
vari
bacteri
toxin
assay
intramacrophag
l
infantum
amastigot
ebola
viru
ricin
toxin
howev
anoth
key
paramet
must
taken
account
evalu
efficaci
level
reduct
intox
infect
given
pathogen
instanc
dt
toxic
reduc
two
log
abma
cell
infect
decreas
rabv
ebov
capac
ctr
progeni
infect
new
cell
practic
abolish
abma
agent
correspond
cell
assay
measur
compound
efficaci
differ
make
comparison
difficult
final
ricin
vivo
assay
demonstr
inhibitor
limit
efficaci
vitro
reduct
ricin
toxic
enough
protect
mice
lethal
toxin
challeng
find
suggest
abma
may
impair
ebola
infect
mice
consid
lowest
ebola
among
test
pathogen
toxin
vitro
sever
broadspectrum
antipathogen
compound
recent
identifi
cellbas
ht
direct
action
host
cell
instead
pathogen
amodiaquin
clinic
approv
drug
treat
malaria
protect
cell
multipl
toxin
anthrax
lethal
toxin
dt
tcdb
virus
ebola
sar
coronaviru
rabi
chikungunya
inhibit
host
cathepsin
bithionol
anthelmint
approv
drug
inhibit
host
caspas
also
reduc
toxic
anthrax
lethal
toxin
dt
cholera
toxin
pseudomona
aeruginosa
exotoxin
botulinum
neurotoxin
ricin
zika
ega
activ
molecul
anthrax
lethal
toxin
also
block
vitro
traffick
variou
toxin
dt
exotoxin
cytoleth
distend
toxin
botulinum
neurotoxin
clostridium
toxin
virus
influenza
viru
lymphocyt
choriomening
viru
acidifi
prove
broadspectrum
action
toxin
ricin
stx
cholera
toxin
virus
ebola
marburg
vaccinia
viru
enteroviru
adenoassoci
viru
polyoma
papillomavirus
intracellular
bacteria
sn
ctr
parasit
leishmania
interf
intracellular
traffick
machineri
eetran
golgi
worth
note
abma
demonstr
efficaci
vivo
even
list
pathogen
test
overlap
public
prevent
insight
comparison
distinct
mode
action
inhibitor
host
cell
particularli
traffick
pathway
may
explain
varieti
antipathogen
spectra
observ
thu
instanc
combin
inhibitor
may
increas
addit
synergist
protect
efficaci
altogeth
result
show
ht
hit
abma
remark
potenti
develop
broadspectrum
drug
toxin
virus
intracellular
bacteria
parasit
abma
hit
ht
reason
hope
obtain
power
broadspectrum
inhibitor
medicin
chemistri
optim
activ
may
improv
term
decreas
concentr
give
maximum
efficaci
increas
level
pathogen
inhibit
abma
carri
hydrophob
adamantan
substitu
adamantan
deriv
develop
sinc
antivir
drug
influenza
viru
howev
amantadin
memantin
ethylamin
inact
dt
intox
ebov
infect
data
shown
indic
adamantan
group
suffici
explain
abma
activ
abma
antivir
adamantin
deriv
must
display
differ
mechan
action
achiev
antivir
effect
specif
cellular
target
compound
abma
yet
identifi
electron
microscopi
reveal
intracellular
accumul
mvbsle
increas
lysotrack
acridin
orang
stain
well
accumul
cholesterol
also
demonstr
abma
act
endosom
pathway
induc
accumul
acid
late
endosom
compart
importantli
integr
organel
unaffect
ee
lysosom
golgi
er
nucleu
natur
virus
inhibit
abma
also
suggest
le
target
abma
ebov
need
niemannpick
diseas
type
protein
cholesterol
transport
lelysosom
protein
enter
cell
rabv
denv
cell
entri
less
well
character
howev
describ
must
enter
le
product
infect
vero
contrast
chikv
sensit
abma
ninetyf
chikv
intern
clathrinco
vesicl
main
intern
pathway
viru
viru
exclus
fuse
ee
le
long
consid
import
sort
station
endocyt
determin
whether
particular
protein
lipid
target
lysosom
degrad
altern
recycl
er
golgi
addit
mvbsle
may
fuse
plasma
membran
releas
endosom
pathway
essenti
sever
toxin
virus
transloc
importantli
le
could
also
suppli
nutrit
ie
cholesterol
membran
protein
develop
bacteria
parasit
insid
host
moreov
similarli
observ
human
cell
abma
fig
knockdown
hela
cell
result
enlarg
mvbsle
increas
ilv
consequ
block
egfr
exit
thu
pharmacolog
interfer
abma
cellular
function
key
regul
late
endocyt
traffick
might
explain
broadspectrum
antipathogen
activ
design
drug
target
le
may
constitut
advantag
strategi
obtain
broadspectrum
drug
mani
intracellular
pathogen
inhibitor
cholesterol
transport
induc
cholesterol
accumul
le
therebi
inhibit
toxin
anthrax
lt
bacteria
chlamydia
virus
vesicular
stomat
viru
denv
hepat
c
viru
abma
also
induc
cholesterol
accumul
work
abma
inhibit
dt
cytotox
similar
protect
factor
data
shown
besid
loss
disrupt
lelysosom
morpholog
inhibit
ebov
thu
mechan
action
abma
host
le
may
produc
multipl
consequ
inhibit
variou
pathogen
summari
identifi
broadspectrum
chemic
inhibitor
hinder
sever
toxin
pathogen
interf
host
specif
late
endosom
compart
protect
mice
lethal
ricin
challeng
without
show
toxic
anim
work
highlight
chemic
harbor
action
cellular
compon
host
potenti
broadspectrum
drug
variou
pathogen
amin
abma
purchas
chembridg
id
san
diego
ca
usa
ricin
screen
anim
experi
vitro
valid
suppli
bruno
toxin
b
tcdb
produc
clostridium
difficil
lethal
toxin
tcsl
produc
clostridium
sordellii
anthrax
toxin
produc
purifi
describ
follow
product
purchas
indic
commerci
sourc
leucin
perkinelm
list
lab
usa
dmso
diphtheria
toxin
dt
bafilomycin
hoechst
filipin
iii
acridin
orang
gelatin
purchas
sigma
follow
commerci
antibodi
use
studi
rabbit
abcam
rabbit
rabbit
cell
signal
rabbit
mous
antibetaactin
sigmaaldrich
rabbit
mous
antichlamydi
trachomati
protein
clone
santa
cruz
technolog
mous
biolegend
mous
antirnp
ribonucleoprotein
conjug
fitc
fujirebio
alexa
antirabbit
alexa
antimous
lysotrack
deep
red
thermofish
scientif
full
descript
ht
procedur
see
previou
anim
studi
done
french
health
product
safeti
agenc
ansm
anim
care
facil
complianc
ansm
committe
polici
accord
european
regul
pathogenfre
six
weekold
femal
balbc
mice
purchas
charl
river
laboratori
l
arbresl
franc
mice
hous
lightdark
cycl
fed
standard
diet
ad
libidum
standard
group
mice
inject
intraperiton
steril
salin
solut
nacl
supplement
dmso
alon
control
variou
dose
abma
one
hour
prior
toxin
administr
mice
anesthet
intraperiton
inject
ketamin
mg
final
rompun
xylazin
mg
final
solut
expos
ricin
intranas
instil
correspond
one
day
drugtreat
group
contain
five
ten
mice
normal
control
contain
ten
mice
surviv
record
daili
data
mice
test
group
compar
untreat
ricinchalleng
mice
log
rank
test
prism
graphpad
inc
san
diego
calif
pvalu
consid
statist
signific
anim
experi
carri
accord
decre
decre
februari
protect
anim
use
scientif
purpos
nation
order
articl
code
rural
european
direct
eec
novemb
direct
european
parliament
council
septemb
protect
anim
use
scientif
purpos
ethic
committe
languedoc
roussillon
ceealr
review
approv
studi
protocol
permit
experi
procedur
experi
describ
supplementari
inform
see
supplement
materi
method
cell
grown
glass
coverslip
one
day
follow
treatment
cell
rins
pb
fix
paraformaldehydepb
min
room
temperatur
three
time
wash
pb
cell
permeabil
saponin
triton
min
subsequ
cell
block
stain
antibodi
final
slide
mount
glass
slide
imag
invert
microscop
tiu
nikon
confoc
microscop
leica
live
stain
fluorophor
labeledcel
presenc
compound
dmso
wash
visual
confoc
microscop
immedi
confluent
cultur
cell
atcc
treat
abma
dmso
h
fix
glutaraldehyd
cacodyl
buffer
ph
h
cell
scrape
collect
rins
cacodyl
buffer
time
pellet
post
fix
osmium
potassium
ferrocyanid
h
process
dehydr
grade
ethanol
seri
infiltr
epon
resin
mix
propylen
oxid
ultrathin
section
nm
stain
oolong
tea
extract
ote
min
follow
lead
citrat
stain
min
examin
transmiss
electron
microscop
oper
kv
data
gener
analyz
studi
includ
publish
articl
supplementari
inform
file
